A Randomized, Open-Label, Multicenter, Global Phase 2 Study of Durvalumab (D), Tremelimumab (T), or D Plus T, in Patients With PD-L1 Low/Negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: CONDOR

Publication date: 1 April 2018
Source:International Journal of Radiation Oncology*Biology*Physics, Volume 100, Issue 5
Author(s): L. Siu, C. Even, R. Mesía, A. Daste, J. Krauss, N.F. Saba, L. Nabell, N.E. Ready, I.Brana Garcia, N. Kotecki, D.P. Zandberg, J. Gilbert, H. Mehanna, A. Jarkowski, G. Melillo, J.M. Armstrong, J. Fayette




http://ift.tt/2piXoRs